Engineered Mesenchymal Stem Cells as Treatment for Cancers: Opportunities, Clinical Applications and Challenges

Area of Science:

• Biomedical Engineering
• Cancer Biology
• Stem Cell Therapy

Background:

• Classical chemotherapy often results in therapy resistance and cancer recurrence due to insufficient targeting.
• Mesenchymal stem cells (MSCs) possess unique properties like multipotency, regeneration, and immunosuppression, with tropism towards tumor sites, offering novel therapeutic avenues.
• While MSC-based therapies are generally safe, their standalone efficacy in cancer treatment is limited.

Purpose of the Study:

• To review cutting-edge methods for engineering mesenchymal stem cells (MSCs) for enhanced cancer therapy.
• To discuss the potential and challenges of translating engineered MSC therapies into clinical settings.
• To provide future perspectives for optimizing MSC engineering to achieve full therapeutic potential in oncology.

Main Methods:

• Review of current literature on genetic engineering techniques applied to MSCs.
• Analysis of viral and non-viral methods for modifying MSCs to overexpress therapeutic proteins.
• Evaluation of strategies to enhance MSC therapeutic efficacy and targeting while preserving cell function.

Main Results:

• Genetic engineering can equip MSCs with specialized delivery roles, significantly increasing their therapeutic potential in cancer treatment.
• Engineered MSCs can be designed to overexpress therapeutic proteins, augmenting their inherent anti-cancer properties.
• Optimization of engineering strategies is crucial to maximize therapeutic benefits and minimize functional impairment of MSCs.

Conclusions:

• Engineered MSCs represent a promising strategy to overcome limitations of traditional cancer therapies.
• Further research and optimization are needed to translate the potential of engineered MSCs into effective clinical applications.
• Future directions involve refining engineering techniques to enhance targeting precision and therapeutic payload delivery for improved cancer patient outcomes.